EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma☆
Article in Annals of Oncology (September 2023)
The most recent citing publications are shown below. View all 3 publications that cite this research output on Dimensions.
Epidemiology, treatments, and related biomarkers of locally advanced or metastatic urothelial carcinoma in Chinese population: A scoping review
Article in Cancer Medicine (June 2023)
Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinoma
Article in International Immunopharmacology (April 2023)